Business context and reporting period
Trulieve Cannabis Corp. filed this unaudited Form 10-Q for the quarter and six months ended June 30, 2023. The vertically integrated, U.S. cannabis operator reported 183 dispensaries and 17 cultivation and processing facilities across its listed markets. Massachusetts was classified as discontinued operations after the company approved an exit during the quarter; Nevada operations were also included in discontinued operations.
Financial performance and position
Amounts below are in U.S. dollars.
| Metric | Q2 2023 | Q2 2022 | First half 2023 | First half 2022 |
|---|---|---|---|---|
| Revenue | $281.8 million | $313.8 million | $567.0 million | $624.4 million |
| Gross profit / margin | $141.6 million / 50.3% | $183.4 million / 58.4% | $291.8 million / 51.5% | $363.2 million / 58.2% |
| Adjusted EBITDA | $78.7 million | $111.0 million | $156.8 million | $216.0 million |
| Net loss attributable to common shareholders | $403.8 million | $22.5 million | $468.0 million | $54.5 million |
| Cash used in operating activities | Not separately presented for the quarter | $23.1 million | $10.3 million |
Q2 continuing-operations net loss was $342.3 million, including a $307.6 million non-cash goodwill impairment; discontinued-operations loss was $64.6 million. The company recorded income tax expense of $34.0 million in Q2 and $69.5 million for the first half despite pretax losses. It cites IRC Section 280E restrictions on deductible expenses for cannabis businesses.
At June 30, cash and cash equivalents were $152.4 million, with another $7.6 million restricted. Total assets were $2.81 billion and total liabilities $1.35 billion. Private placement notes had $555 million face value, including $130 million due in 2024 and $425 million due in 2026; notes payable had $103.7 million face value. These amounts exclude lease and construction-finance obligations. First-half investing cash use was $25.3 million and financing cash use was $9.3 million; cash and cash equivalents declined from $207.2 million at year-end 2022. Management said existing cash should meet anticipated requirements for at least 12 months.
Material changes versus comparable periods
- Q2 revenue fell 10% year over year; first-half revenue fell 9%. Management attributed the declines to competition and promotional activity, with lower retail and wholesale sales.
- Gross margin fell to 50.3% in Q2 from 58.4%. The company cited price compression, promotions, a shift toward value products, inventory-reduction efforts, excess capacity at temporarily idled facilities, and costs of expansion and less-vertically-integrated markets.
- Adjusted EBITDA declined 29% in Q2 and 27% for the first half. General and administrative expense included $8.6 million of Florida adult-use ballot initiative contributions in Q2 and $19.1 million for the first half.
- First-half operating cash use increased to $23.1 million from $10.3 million, primarily because deferred income-tax payments were made in Q1 2023; inventory reductions partly offset the cash outflow. Capital spending was substantially lower than in the prior-year period.
- The $307.6 million goodwill impairment followed a market-approach valuation in which fair value fell below carrying value. Management attributed the impairment to cannabis-market and stock-price conditions, not operating performance, and said it did not affect cash flow, liquidity, or debt-covenant compliance.
Outlook, commentary, risks and unusual items
- No specific revenue, earnings, or other financial guidance is provided. Management expects existing cash to cover anticipated needs for at least 12 months and describes cash from operations, potential equity offerings, and possible debt as sources of additional capital.
- The Massachusetts exit resulted in discontinued-operations losses, including asset-disposal charges; the filing reports a $95.9 million discontinued-operations loss for the first half. The company also divested three California dispensaries during Q2.
- The CFO resigned in June 2023. A successor appointed in July resigned shortly afterward, and Ryan Blust was again named interim CFO. An audit committee investigation found the former CFO submitted personal expenses for reimbursement and used a corporate card for personal expenses; the company estimated $350,000–$400,000 was in question, had not been repaid, and was evaluating recovery and possible corrective tax reporting. The company said the matter did not materially affect previously reported financial statements.
- Disclosure controls were deemed ineffective as of June 30 because previously identified material weaknesses in IT controls, inventory valuation, and identification and evaluation of variable-interest entities remained under remediation. Management said the included financial statements fairly presented the company’s position and results in all material respects.
- Key risks include federal cannabis illegality and potential enforcement or asset forfeiture, state licensing and regulatory compliance, competition and price pressure, Section 280E taxation, significant debt and financing access, and the disclosed control weaknesses. The company also noted cash deposits exceed FDIC insurance limits.
Important facts for investors to verify
- Whether revenue, gross-margin pressure, and Adjusted EBITDA trends improve, and how much the margin decline reflects temporary inventory actions versus continuing market conditions.
- Liquidity and debt-service capacity, especially the $130 million of private placement notes due in 2024, covenant terms, and management’s 12-month liquidity assessment.
- The financial and operational consequences of exiting Massachusetts, including remaining lease and construction-finance obligations and asset-disposal outcomes.
- Progress in remediating the material weaknesses and whether the former CFO expense matter results in recovery or corrective tax reporting.
- The assumptions behind the goodwill valuation and any subsequent changes in cannabis-market conditions, federal policy, taxation, or access to banking services.